BG107798A - Adjuvant combination formulations - Google Patents

Adjuvant combination formulations Download PDF

Info

Publication number: BG107798A
Authority: BG; Bulgaria
Prior art keywords: arg; asn; lys; lie; gly
Prior art date: 2000-11-10

Application number

BG107798A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael Hagen

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-10

Filing date

2003-05-10

Publication date

2004-07-30

2003-05-10 Application filed by Wyeth Corp filed Critical Wyeth Corp

2004-07-30 Publication of BG107798A publication Critical patent/BG107798A/bg

Links

239000002671 adjuvant Substances 0.000 title claims abstract description 114
239000000203 mixture Substances 0.000 title claims abstract description 102
238000009472 formulation Methods 0.000 title description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 170
102000036639 antigens Human genes 0.000 claims abstract description 100
108091007433 antigens Proteins 0.000 claims abstract description 100
239000000427 antigen Substances 0.000 claims abstract description 98
102000004127 Cytokines Human genes 0.000 claims abstract description 72
108090000695 Cytokines Proteins 0.000 claims abstract description 72
230000000890 antigenic effect Effects 0.000 claims abstract description 64
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 35
102000013462 Interleukin-12 Human genes 0.000 claims abstract description 34
108010065805 Interleukin-12 Proteins 0.000 claims abstract description 34
230000028993 immune response Effects 0.000 claims abstract description 31
229940117681 interleukin-12 Drugs 0.000 claims abstract description 30
241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 19
-1 aminoalkyl glucosamine phosphate compound Chemical class 0.000 claims abstract description 11
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 7
229960002442 glucosamine Drugs 0.000 claims abstract description 7
229910019142 PO4 Inorganic materials 0.000 claims abstract description 5
239000010452 phosphate Substances 0.000 claims abstract description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 198
241000725303 Human immunodeficiency virus Species 0.000 claims description 58
210000004027 cell Anatomy 0.000 claims description 42
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 42
102000004196 processed proteins & peptides Human genes 0.000 claims description 37
238000000034 method Methods 0.000 claims description 34
241000700605 Viruses Species 0.000 claims description 33
108090000623 proteins and genes Proteins 0.000 claims description 32
102000004169 proteins and genes Human genes 0.000 claims description 31
LANZYLJEHLBUPR-BPUTZDHNSA-N Asn-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)N)N LANZYLJEHLBUPR-BPUTZDHNSA-N 0.000 claims description 30
108010032388 glycyl-prolyl-glycyl-arginyl-alanyl-phenylanine Proteins 0.000 claims description 29
125000003275 alpha amino acid group Chemical group 0.000 claims description 28
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 claims description 28
230000000694 effects Effects 0.000 claims description 22
239000012634 fragment Substances 0.000 claims description 19
VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 claims description 18
HOTNHEUETJELDL-BPNCWPANSA-N Met-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N HOTNHEUETJELDL-BPNCWPANSA-N 0.000 claims description 18
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 18
GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 claims description 17
101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 16
101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 16
102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 16
108010001271 arginyl-glutamyl-arginine Proteins 0.000 claims description 15
230000002708 enhancing effect Effects 0.000 claims description 15
239000007764 o/w emulsion Substances 0.000 claims description 15
230000001717 pathogenic effect Effects 0.000 claims description 15
241000894006 Bacteria Species 0.000 claims description 14
241000233866 Fungi Species 0.000 claims description 14
KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 claims description 14
244000045947 parasite Species 0.000 claims description 14
RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 claims description 13
239000000556 agonist Substances 0.000 claims description 12
201000011510 cancer Diseases 0.000 claims description 12
229920001184 polypeptide Polymers 0.000 claims description 12
WQWZXKWOEVSGQM-DCAQKATOSA-N Lys-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN WQWZXKWOEVSGQM-DCAQKATOSA-N 0.000 claims description 11
PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 claims description 11
239000013566 allergen Substances 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 claims description 10
UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 claims description 10
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 claims description 8
HNJNAMGZQZPSRE-GUBZILKMSA-N Arg-Pro-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O HNJNAMGZQZPSRE-GUBZILKMSA-N 0.000 claims description 8
ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 claims description 8
NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 claims description 8
AYPAIRCDLARHLM-KKUMJFAQSA-N Tyr-Asn-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O AYPAIRCDLARHLM-KKUMJFAQSA-N 0.000 claims description 8
HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 claims description 7
108010008237 glutamyl-valyl-glycine Proteins 0.000 claims description 7
210000004881 tumor cell Anatomy 0.000 claims description 7
108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 claims description 7
XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 claims description 5
KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 claims description 5
IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 claims description 5
SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 claims description 5
ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 claims description 5
XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims description 5
MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 claims description 5
JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 claims description 5
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 claims description 5
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 5
108010087823 glycyltyrosine Proteins 0.000 claims description 5
108010028295 histidylhistidine Proteins 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 claims description 4
ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 claims description 4
230000003941 amyloidogenesis Effects 0.000 claims description 4
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 claims description 3
AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 claims description 3
230000001093 anti-cancer Effects 0.000 claims description 3
230000004807 localization Effects 0.000 claims description 3
230000000069 prophylactic effect Effects 0.000 claims description 3
DXTYEWAQOXYRHZ-KKXDTOCCSA-N Ala-Phe-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N DXTYEWAQOXYRHZ-KKXDTOCCSA-N 0.000 claims description 2
ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 claims description 2
IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 claims description 2
NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
108010062796 arginyllysine Proteins 0.000 claims description 2
230000005745 host immune response Effects 0.000 claims description 2
108010079317 prolyl-tyrosine Proteins 0.000 claims description 2
BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 claims 10
UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 claims 6
108010060035 arginylproline Proteins 0.000 claims 5
QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 claims 4
VKCOHFFSTKCXEQ-OLHMAJIHSA-N Asn-Asn-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VKCOHFFSTKCXEQ-OLHMAJIHSA-N 0.000 claims 4
YWEHYKGJWHPGPY-XGEHTFHBSA-N Cys-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N)O YWEHYKGJWHPGPY-XGEHTFHBSA-N 0.000 claims 4
VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 claims 4
MLQVJYMFASXBGZ-IHRRRGAJSA-N Pro-Asn-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O MLQVJYMFASXBGZ-IHRRRGAJSA-N 0.000 claims 4
CWZUFLWPEFHWEI-IHRRRGAJSA-N Pro-Tyr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O CWZUFLWPEFHWEI-IHRRRGAJSA-N 0.000 claims 4
KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 claims 4
108010015792 glycyllysine Proteins 0.000 claims 3
CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 claims 2
SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 claims 2
FVNAUOZKIPAYNA-BPNCWPANSA-N Ala-Met-Tyr Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FVNAUOZKIPAYNA-BPNCWPANSA-N 0.000 claims 1
VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 claims 1
JXMREEPBRANWBY-VEVYYDQMSA-N Asn-Thr-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JXMREEPBRANWBY-VEVYYDQMSA-N 0.000 claims 1
HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 claims 1
BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 claims 1
LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 claims 1
NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 claims 1
NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 claims 1
LZWNAOIMTLNMDW-NHCYSSNCSA-N Lys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N LZWNAOIMTLNMDW-NHCYSSNCSA-N 0.000 claims 1
VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 claims 1
108010033276 Peptide Fragments Proteins 0.000 claims 1
102000007079 Peptide Fragments Human genes 0.000 claims 1
WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 claims 1
YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 claims 1
JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 143
241001465754 Metazoa Species 0.000 description 80
238000002649 immunization Methods 0.000 description 69
230000003053 immunization Effects 0.000 description 67
230000002163 immunogen Effects 0.000 description 41
241000699670 Mus sp. Species 0.000 description 36
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical group O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 28
235000018102 proteins Nutrition 0.000 description 28
210000002966 serum Anatomy 0.000 description 28
241000699666 Mus <mouse, genus> Species 0.000 description 27
230000004044 response Effects 0.000 description 26
238000002474 experimental method Methods 0.000 description 25
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 18
230000003472 neutralizing effect Effects 0.000 description 18
239000003921 oil Substances 0.000 description 17
210000004698 lymphocyte Anatomy 0.000 description 16
230000024932 T cell mediated immunity Effects 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
239000000839 emulsion Substances 0.000 description 13
230000006698 induction Effects 0.000 description 13
102000004388 Interleukin-4 Human genes 0.000 description 12
108090000978 Interleukin-4 Proteins 0.000 description 12
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 12
238000011830 transgenic mouse model Methods 0.000 description 12
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 11
238000002965 ELISA Methods 0.000 description 10
108010002350 Interleukin-2 Proteins 0.000 description 10
102000000588 Interleukin-2 Human genes 0.000 description 10
102000008072 Lymphokines Human genes 0.000 description 10
108010074338 Lymphokines Proteins 0.000 description 10
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
210000001744 T-lymphocyte Anatomy 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
241000282412 Homo Species 0.000 description 9
230000005875 antibody response Effects 0.000 description 9
238000010186 staining Methods 0.000 description 9
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
230000003834 intracellular effect Effects 0.000 description 8
210000004988 splenocyte Anatomy 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
241000282560 Macaca mulatta Species 0.000 description 7
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 7
239000011651 chromium Substances 0.000 description 7
238000011161 development Methods 0.000 description 7
230000028996 humoral immune response Effects 0.000 description 7
238000010255 intramuscular injection Methods 0.000 description 7
239000007927 intramuscular injection Substances 0.000 description 7
239000000863 peptide conjugate Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 6
206010018341 Gliosis Diseases 0.000 description 6
206010047700 Vomiting Diseases 0.000 description 6
230000002411 adverse Effects 0.000 description 6
208000037875 astrocytosis Diseases 0.000 description 6
230000007341 astrogliosis Effects 0.000 description 6
229910052804 chromium Inorganic materials 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
239000012636 effector Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
244000052769 pathogen Species 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 5
241000759568 Corixa Species 0.000 description 5
206010022095 Injection Site reaction Diseases 0.000 description 5
241000282376 Panthera tigris Species 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000036755 cellular response Effects 0.000 description 5
230000001054 cortical effect Effects 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
210000002241 neurite Anatomy 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
102000008070 Interferon-gamma Human genes 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
241001529936 Murinae Species 0.000 description 4
241000288906 Primates Species 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
206010000269 abscess Diseases 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
108091033319 polynucleotide Proteins 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
239000004474 valine Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
241000282553 Macaca Species 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000005153 frontal cortex Anatomy 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
102000046157 human CSF2 Human genes 0.000 description 3
230000002519 immonomodulatory effect Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
241000271566 Aves Species 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
241000186359 Mycobacterium Species 0.000 description 2
241000224526 Trichomonas Species 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
241000700647 Variola virus Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
206010002022 amyloidosis Diseases 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000007366 host health Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
229940035032 monophosphoryl lipid a Drugs 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
210000003314 quadriceps muscle Anatomy 0.000 description 2
230000000384 rearing effect Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229940038774 squalene oil Drugs 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
239000013598 vector Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
241000186033 Alloiococcus Species 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
241000244186 Ascaris Species 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
241000335423 Blastomyces Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
101100508409 Caenorhabditis elegans ifa-4 gene Proteins 0.000 description 1
101100508407 Caenorhabditis elegans mua-6 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000714165 Feline leukemia virus Species 0.000 description 1
241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
241000224466 Giardia Species 0.000 description 1
JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010030912 HIV envelope protein gp120 (305-321) Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000893570 Hendra henipavirus Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000606831 Histophilus somni Species 0.000 description 1
241000228402 Histoplasma Species 0.000 description 1
101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100032818 Integrin alpha-4 Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000222732 Leishmania major Species 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
241000589929 Leptospira interrogans Species 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
108010008707 Mucin-1 Proteins 0.000 description 1
101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204022 Mycoplasma gallisepticum Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000282579 Pan Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
101800001357 Potential peptide Proteins 0.000 description 1
102400000745 Potential peptide Human genes 0.000 description 1
102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
241000588767 Proteus vulgaris Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
206010051497 Rhinotracheitis Diseases 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
241001489151 Trichuris Species 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
241000711955 Turkey rhinotracheitis virus Species 0.000 description 1
NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
108010011559 alanylphenylalanine Proteins 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
150000002301 glucosamine derivatives Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000007119 pathological manifestation Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940007042 proteus vulgaris Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000000523 sample Substances 0.000 description 1
FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG107798A 2000-11-10 2003-05-10 Adjuvant combination formulations BG107798A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24710000P	2000-11-10	2000-11-10
US33034501P	2001-10-18	2001-10-18
PCT/US2001/046943 WO2002038177A2 (en)	2000-11-10	2001-11-08	Adjuvant combination formulations

Publications (1)

Publication Number	Publication Date
BG107798A true BG107798A (en)	2004-07-30

Family

ID=26938452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107798A BG107798A (en)	2000-11-10	2003-05-10	Adjuvant combination formulations

Country Status (26)

Country	Link
US (2)	US20040156820A1 (cs)
EP (1)	EP1343527A2 (cs)
JP (2)	JP2004523483A (cs)
KR (1)	KR100863368B1 (cs)
CN (1)	CN1533285A (cs)
AU (2)	AU2002225972B2 (cs)
BG (1)	BG107798A (cs)
BR (1)	BR0115271A (cs)
CA (1)	CA2429000A1 (cs)
CZ (1)	CZ20031225A3 (cs)
EA (1)	EA004744B1 (cs)
EE (1)	EE200300172A (cs)
EG (1)	EG24378A (cs)
GE (1)	GEP20074077B (cs)
HR (1)	HRP20030355A2 (cs)
HU (1)	HUP0600589A2 (cs)
IL (1)	IL155690A0 (cs)
IS (1)	IS6809A (cs)
MX (1)	MXPA03004071A (cs)
NO (1)	NO20032086L (cs)
NZ (1)	NZ525887A (cs)
PE (1)	PE20020530A1 (cs)
PL (1)	PL366031A1 (cs)
SK (1)	SK5482003A3 (cs)
TW (1)	TWI239848B (cs)
WO (1)	WO2002038177A2 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9326174D0 (en) *	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
SI2336147T1 (sl)	2003-12-17	2014-08-29	Janssen Alzheimer Immunotherapy	Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
WO2006047670A2 (en) *	2004-10-26	2006-05-04	Wyeth	Methods for assessing antibodies to neurodegenerative disease-associated antigens
KR100878585B1 (ko)	2006-06-16	2009-01-15	국립암센터	글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
US9498522B2 (en)	2008-08-07	2016-11-22	Mercia Pharma Inc.	Immunotherapeutic compositions for the treatment of alzheimer'S disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en)	1985-08-16	1992-01-07	Immunex Corporation	Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US6294322B1 (en)	1988-01-26	2001-09-25	The United States Of America As Represented By The Department Of Health And Human Services	Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5939074A (en)	1986-12-30	1999-08-17	The United States Of America As Represented By The Department Of Health And Human Services	Multideterminant peptide antigens
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5993819A (en) *	1987-09-08	1999-11-30	Duke University	Synthetic vaccine for protection against human immunodeficiency virus infection
US5013548A (en)	1987-09-08	1991-05-07	Duke University	Production of antibodies to HIV
US5019387A (en) *	1987-09-08	1991-05-28	Duke University	Production of antibodies to HIV
US5223254A (en) *	1987-09-29	1993-06-29	Praxis Biologics, Inc.	Respiratory syncytial virus: vaccines
CA1340506C (en) *	1987-11-24	1999-04-20	Nicholas H. Carbonetti	Production of gonorrheal pi proteins and vaccines
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
WO1990005147A1 (en)	1988-11-10	1990-05-17	Genetics Institute, Inc.	Natural killer stimulatory factor
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
DE3934366A1 (de)	1989-10-14	1991-04-18	Chemotherapeutisches Forschungsinstitut Georg Speyer Haus	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
EP0671947B1 (en)	1991-12-02	2000-03-08	The Board Of Regents, The University Of Texas System	Compositions for eliciting cytotoxic t-lymphocyte responses against viruses
US6037135A (en) *	1992-08-07	2000-03-14	Epimmune Inc.	Methods for making HLA binding peptides and their uses
MX9304089A (es) *	1992-07-08	1994-01-31	Schering Corp	Uso de gm-csf como una vacuna adyuvante.
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
KR100310510B1 (ko) *	1993-03-23	2002-07-04	장 스테판느	3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
RU2160119C2 (ru) *	1993-05-25	2000-12-10	Американ Цианамид Компани	Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
US5830877A (en) *	1993-08-26	1998-11-03	The Regents Of The University Of California	Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5571515A (en) *	1994-04-18	1996-11-05	The Wistar Institute Of Anatomy & Biology	Compositions and methods for use of IL-12 as an adjuvant
AUPM543894A0 (en) *	1994-05-04	1994-05-26	Commonwealth Scientific And Industrial Research Organisation	An adjuvant
US5679256A (en) *	1994-06-20	1997-10-21	Rose; Jane Anne	In-situ groundwater clean-up and radionuclide disposal method
PT784486E (pt) *	1994-10-05	2006-07-31	Univ Vanderbilt	Inerleucina-12 como um adjuvante para vacinas contra paramyxoviridae
US5939075A (en) *	1994-11-04	1999-08-17	The United States Of America As Represented By The Secretary Of The Army	Mutants of Brucella melitensis
AU4727296A (en) *	1995-02-24	1996-09-11	Cantab Pharmaceuticals Research Limited	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6613337B1 (en) *	1997-02-12	2003-09-02	Corixa Corporation	Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
JPH09124697A (ja) *	1995-11-01	1997-05-13	Toagosei Co Ltd	ペプチド及びモノクローナル抗体
US6096313A (en) *	1996-02-09	2000-08-01	Ludwig Institute For Cancer Research	Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5762943A (en) *	1996-05-14	1998-06-09	Ribi Immunochem Research, Inc.	Methods of treating type I hypersensitivity using monophosphoryl lipid A
AU724743B2 (en) *	1996-05-31	2000-09-28	Genetics Institute, Llc	IL-12 as an adjuvant for Bordetella Pertussis vaccines
US6024965A (en)	1996-10-18	2000-02-15	Erasums University Rotterdam	Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US6797276B1 (en) *	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6350456B1 (en) *	1997-03-13	2002-02-26	Corixa Corporation	Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6113918A (en) *	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) *	1997-06-14	1997-08-13	Smithkline Beecham Biolog	Vaccine
IS4518A (is) *	1997-07-09	1999-01-10	Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group	Nýtt lyfjaform fyrir bóluefni
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2002502884A (ja) *	1998-02-12	2002-01-29	アメリカン・サイアナミド・カンパニー	インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
GB9907860D0 (en) *	1999-04-07	1999-06-02	Smithkline Beecham Biolog	Novel compounds
ID30407A (id)	1999-05-13	2001-11-29	American Cyanamid Co	Formulasi-formulasi kombinasi bahan penambah
US7396535B2 (en) *	2003-04-25	2008-07-08	Ackerman Alan H	Therapy for obsessive compulsive head banging

2001
- 2001-11-08 WO PCT/US2001/046943 patent/WO2002038177A2/en not_active Ceased
- 2001-11-08 EP EP01993474A patent/EP1343527A2/en not_active Withdrawn
- 2001-11-08 US US10/416,262 patent/US20040156820A1/en not_active Abandoned
- 2001-11-08 IL IL15569001A patent/IL155690A0/xx unknown
- 2001-11-08 GE GE5203A patent/GEP20074077B/en unknown
- 2001-11-08 BR BR0115271-8A patent/BR0115271A/pt not_active IP Right Cessation
- 2001-11-08 EE EEP200300172A patent/EE200300172A/xx unknown
- 2001-11-08 CA CA002429000A patent/CA2429000A1/en not_active Abandoned
- 2001-11-08 NZ NZ525887A patent/NZ525887A/en unknown
- 2001-11-08 CZ CZ20031225A patent/CZ20031225A3/cs unknown
- 2001-11-08 AU AU2002225972A patent/AU2002225972B2/en not_active Ceased
- 2001-11-08 MX MXPA03004071A patent/MXPA03004071A/es not_active Application Discontinuation
- 2001-11-08 EA EA200300557A patent/EA004744B1/ru not_active IP Right Cessation
- 2001-11-08 PE PE2001001106A patent/PE20020530A1/es not_active Application Discontinuation
- 2001-11-08 SK SK548-2003A patent/SK5482003A3/sk not_active Application Discontinuation
- 2001-11-08 HR HR20030355A patent/HRP20030355A2/hr not_active Application Discontinuation
- 2001-11-08 PL PL01366031A patent/PL366031A1/xx not_active Application Discontinuation
- 2001-11-08 AU AU2597202A patent/AU2597202A/xx active Pending
- 2001-11-08 JP JP2002540759A patent/JP2004523483A/ja active Pending
- 2001-11-08 HU HU0600589A patent/HUP0600589A2/hu unknown
- 2001-11-08 CN CNA018213863A patent/CN1533285A/zh active Pending
- 2001-11-08 KR KR1020037006366A patent/KR100863368B1/ko not_active Expired - Fee Related
- 2001-11-09 TW TW090127895A patent/TWI239848B/zh active
- 2001-11-10 EG EG2001111183A patent/EG24378A/xx active
2003
- 2003-05-07 IS IS6809A patent/IS6809A/is unknown
- 2003-05-09 NO NO20032086A patent/NO20032086L/no not_active Application Discontinuation
- 2003-05-10 BG BG107798A patent/BG107798A/bg unknown
2006
- 2006-10-06 US US11/544,056 patent/US20070025959A1/en not_active Abandoned
2009
- 2009-08-21 JP JP2009192001A patent/JP2010001304A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2002225972B2 (en)	2006-06-29
IL155690A0 (en)	2003-11-23
CA2429000A1 (en)	2002-05-16
IS6809A (is)	2003-05-07
TWI239848B (en)	2005-09-21
WO2002038177A3 (en)	2003-01-16
EP1343527A2 (en)	2003-09-17
EE200300172A (et)	2003-06-16
CN1533285A (zh)	2004-09-29
JP2004523483A (ja)	2004-08-05
GEP20074077B (en)	2007-03-26
JP2010001304A (ja)	2010-01-07
EA004744B1 (ru)	2004-08-26
PL366031A1 (en)	2005-01-24
KR100863368B1 (ko)	2008-10-13
PE20020530A1 (es)	2002-06-18
MXPA03004071A (es)	2003-09-04
US20040156820A1 (en)	2004-08-12
NZ525887A (en)	2005-08-26
NO20032086L (no)	2003-07-07
HUP0600589A2 (en)	2006-11-28
NO20032086D0 (no)	2003-05-09
SK5482003A3 (en)	2004-03-02
KR20040043098A (ko)	2004-05-22
EA200300557A1 (ru)	2004-04-29
EG24378A (en)	2009-03-26
WO2002038177A2 (en)	2002-05-16
HRP20030355A2 (en)	2005-04-30
CZ20031225A3 (cs)	2003-10-15
BR0115271A (pt)	2005-12-13
US20070025959A1 (en)	2007-02-01
AU2597202A (en)	2002-05-21

Publication	Publication Date	Title
JP5230780B2 (ja)	2013-07-10	アジュバント混合製剤
CA2409406C (en)	2010-09-14	Qs-21 and il-12 as an adjuvant combination
AU2001270031A1 (en)	2002-03-21	QS-21 and IL-12 as an adjuvant combination
JP2010001304A (ja)	2010-01-07	アジュバントの組合せ製剤
AU2002225972A1 (en)	2002-07-25	Adjuvant combination formulations
JP2002502883A (ja)	2002-01-29	インターロイキン−１２および呼吸合法体ウイルス抗原を含んで成るワクチン
ZA200304479B (en)	2004-09-09	Adjuvant combination formulations.